Lupus Science & Medicine

Papers
(The TQCC of Lupus Science & Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis178
Mortality patterns of SLE and the associated risk factors in Korean patients: a nationwide cohort study49
COVID-19 vaccination questionnaire in patients with systemic lupus erythematosus: an observational study46
Scleroderma-like capillaroscopic pattern in SLE is not a sign of overlap syndrome in both adults and children40
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE40
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria39
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms37
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up32
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study32
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children29
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study27
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus27
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology26
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases26
Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)23
Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study23
High-density lipoprotein cholesterol subfraction HDL2 is associated with improved endothelial function in systemic lupus erythematosus22
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus22
Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay andCrithidia luciliaeassay in a multiethnic racial cohort of patients with SLE22
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins20
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms20
Genetic load in incomplete lupus erythematosus19
Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)19
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field19
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus19
Comparing dermatologic patient-reported outcome measures in cutaneous lupus erythematosus19
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)18
Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blin18
Prevalence of coeliac disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis17
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease17
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis17
Activation-induced colocalisation of SCAMP5 with IFNα in human plasmacytoid dendritic cells16
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort16
Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE16
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption15
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol15
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE15
Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice15
Validating claims-based algorithms for a systemic lupus erythematosus diagnosis in Medicare data for informed use of the Lupus Index: a tool for geospatial research14
Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome13
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis13
Impact of disease activity patterns on health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE)13
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients13
Cutaneous lupus concerns from the patient perspective: a qualitative study13
Altered structural and functional homotopic connectivity associated with cognitive changes in SLE13
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes13
Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital12
Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study12
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus12
Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study12
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis12
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus12
Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study12
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history11
Breastfeeding in women with rheumatic diseases11
Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Stu11
Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort11
Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus11
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE11
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine11
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density11
Ras-MAPK pathway in patients with lupus nephritis11
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study11
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?11
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis11
Canadian workplace experiences of systemic lupus erythematosus (SLE)10
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus10
Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology10
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis10
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state10
Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study10
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lu10
Molecular signatures of intrarenal complement receptorsC3AR1andC5AR1correlate with renal outcome in human lupus nephritis10
Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity10
Towards an understanding of the biopsychosocial determinants of CVD in SLE: a scoping review10
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial10
Intermuscular adipose tissue in patients with systemic lupus erythematosus9
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus9
Circulating extracellular vesicles in Systemic Lupus Erythematosus: physicochemical properties and phenotype9
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?9
Potential involvement of circulating exosomal miRNA-146a in disease activity andTRAF6gene expression in juvenile proliferative lupus nephritis9
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis9
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus9
Development and validation of a risk scoring system to identify patients with lupus nephritis in electronic health record data9
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study9
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-1329
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory9
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease9
Abnormally high expression of D1-like dopamine receptors on lupus CD4+T cells promotes Tfh cell differentiation9
CD4+T-cell cooperation promoted pathogenic function of activated naïve B cells of patients with SLE9
Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review8
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE8
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus8
Cross-sectional study of the effects of self-efficacy on fatigue and pain interference in black women with systemic lupus erythematosus: the role of depression, age and education8
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort8
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica8
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit8
0.045574903488159